Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments

dc.contributor.author	Mbori-Ngacha, DA
dc.contributor.author	Richardson, BA
dc.contributor.author	Overbaugh, J
dc.contributor.author	Panteleeff, DD
dc.contributor.author	Nduati, RW
dc.contributor.author	Steele, M
dc.contributor.author	John-Stewart, G
dc.date.accessioned	2013-06-10T07:53:22Z
dc.date.available	2013-06-10T07:53:22Z
dc.date.issued	2003-07
dc.identifier.citation	J Virol. 2003 Jul;77(13):7702-5.	en
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/12805473
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30446
dc.description.abstract	The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions	en
dc.language.iso	en	en
dc.publisher	University of Nairobi.	en
dc.title	Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments	en
dc.type	Article	en
local.publisher	Department of Pediatrics, University of Nairobi, Nairobi, Kenya	en